Arbutus to Present Imdusiran Data at EASL Congress 2024
22 Maggio 2024 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the
“Company”), a clinical-stage biopharmaceutical company leveraging
its extensive virology expertise to develop a functional cure for
people with chronic hepatitis B virus (cHBV) infection, today
announced that two abstracts have been accepted for poster and oral
presentations at the European Association for the Study of the
Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan,
Italy.
The accepted abstracts for presentation are as
follows:
Abstract Number:
2389Presentation Type: Poster
presentationTitle: Imdusiran (AB-729) administered
every 8 weeks in combination with 24 weeks of pegylated interferon
alfa-2a in virally suppressed, HBeAg-negative subjects with chronic
HBV infection leads to HBsAg loss in some subjects at end of IFN
treatment.Presenter: Prof. Man-Fung
YuenPresentation Date: June 5, 2024Key
Findings: HBsAg ≤ LLOQ (lower limit of quantification)
with detectable anti-HBs was observed at end-of-treatment in 28% of
subjects who received 4 or 6 doses of imdusiran plus 24 weeks of
IFN, but in 0 subjects who received 4 or 5 doses of imdusiran plus
12 weeks of IFN. The study remains ongoing and additional
end-of-treatment data, durability of end-of-treatment HBsAg loss,
and preliminary immunology data for a subset of study subjects will
be presented.
This poster will also be featured in the Poster
Tour: Viral hepatitis B and D: New therapies, unapproved therapies
or strategies, on Thursday, June 6.
Abstract Number:
505Presentation Type: Oral
presentationTitle: Imdusiran (AB-729) administered
every 8 weeks for 24 weeks followed by the immunotherapeutic
VTP-300 maintains lower HBV surface antigen levels in NA-suppressed
CHB subjects than 24 weeks of imdusiran
alone.Presenter: Prof. Kosh
AgarwalPresentation Date: June 6, 2024Key
Findings: Repeat dosing of imdusiran for 24 weeks followed
by VTP-300 was well-tolerated and contributes to the maintenance of
lower HBsAg levels compared to placebo in subjects who have reached
end-of-treatment and follow up week 60. More subjects who received
VTP-300 have qualified to stop NA-therapy at end-of-treatment and
all remain off therapy. Additional on-treatment, follow-up and NA
discontinuation data will be presented.
Abstracts are available on the EASL Congress
2024 website at https://www.easlcongress.eu/. The posters are
expected to be made available to conference attendees at the start
of the meeting on June 5, 2024. The poster and oral presentation
will be available subsequently on Arbutus’ website at
https://www.arbutusbio.com/publications/.
About imdusiran
(AB-729)Imdusiran is an RNA interference (RNAi)
therapeutic specifically designed to reduce all HBV viral proteins
and antigens including hepatitis B surface antigen, which is
thought to be a key prerequisite to enable reawakening of a
patient’s immune system to respond to the virus. Imdusiran targets
hepatocytes using Arbutus’ novel covalently conjugated
N-Acetylgalactosamine (GalNAc) delivery technology enabling
subcutaneous delivery. Clinical data generated thus far has shown
single and multiple doses of imdusiran to be generally safe and
well-tolerated, while also providing meaningful reductions in
hepatitis B surface antigen and hepatitis B DNA. Imdusiran is
currently in multiple Phase 2a clinical trials.
About HBVHepatitis B is a
potentially life-threatening liver infection caused by the
hepatitis B virus (HBV). HBV can cause chronic infection which
leads to a higher risk of death from cirrhosis and liver cancer.
Chronic HBV infection represents a significant unmet medical need.
The World Health Organization estimates that over 290 million
people worldwide suffer from chronic HBV infection, while other
estimates indicate that approximately 2.4 million people in the
United States suffer from chronic HBV infection. Approximately
820,000 people die every year from complications related to chronic
HBV infection despite the availability of effective vaccines and
current treatment options.
About ArbutusArbutus Biopharma
Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical
company leveraging its extensive virology expertise to identify and
develop novel therapeutics with distinct mechanisms of action,
which can be combined to provide a functional cure for patients
with chronic hepatitis B virus (cHBV). We believe the key to
success in developing a functional cure involves suppressing HBV
DNA, reducing surface antigen, and boosting HBV-specific immune
responses. Our pipeline of internally developed, proprietary
compounds includes an RNAi therapeutic, imdusiran (AB-729), and an
oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful
clinical data demonstrating an impact on both surface antigen
reduction and reawakening of the HBV-specific immune response.
Imdusiran is currently in three Phase 2a combination clinical
trials. AB-101 is currently being evaluated in a Phase 1a/1b
clinical trial. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and
InformationThis press release contains forward-looking
statements within the meaning of the Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
and forward-looking information within the meaning of Canadian
securities laws (collectively, forward-looking statements).
Forward-looking statements in this press release include statements
about our future development plans for our product candidates; the
expected results of our clinical development plans and clinical
trials with respect to our product candidates; our expectations
with respect to the release of data from our clinical trials and
the expected timing thereof; and the potential for our product
candidates to achieve success in clinical trials.
With respect to the forward-looking statements
contained in this press release, Arbutus has made numerous
assumptions regarding, among other things: the effectiveness and
timeliness of preclinical studies and clinical trials, and the
usefulness of the data; the timeliness of regulatory approvals; the
continued demand for Arbutus’ assets; and the stability of economic
and market conditions. While Arbutus considers these assumptions to
be reasonable, these assumptions are inherently subject to
significant business, economic, competitive, market and social
uncertainties and contingencies.
Additionally, there are known and unknown risk
factors which could cause Arbutus’ actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements contained herein. Known risk factors
include, among others: anticipated pre-clinical studies and
clinical trials may be more costly or take longer to complete than
anticipated, and may never be initiated or completed, or may not
generate results that warrant future development of the tested
product candidate; Arbutus may elect to change its strategy
regarding its product candidates and clinical development
activities; Arbutus may not receive the necessary regulatory
approvals for the clinical development of Arbutus’ products;
economic and market conditions may worsen; market shifts may
require a change in strategic focus.
A more complete discussion of the risks and
uncertainties facing Arbutus appears in Arbutus’ Annual Report on
Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’
continuous and periodic disclosure filings, which are available at
www.sedar.com and at www.sec.gov. All forward-looking statements
herein are qualified in their entirety by this cautionary
statement, and Arbutus disclaims any obligation to revise or update
any such forward-looking statements or to publicly announce the
result of any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments,
except as required by law.
Contact Information
Investors and MediaLisa M. CaperelliVice
President, Investor RelationsPhone: 215-206-1822Email:
lcaperelli@arbutusbio.com
Grafico Azioni Arbutus Biopharma (NASDAQ:ABUS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Arbutus Biopharma (NASDAQ:ABUS)
Storico
Da Giu 2023 a Giu 2024